HAOHAI BIOTEC News

Haohai Biotech (688366): Short-term collection affects performance growth, optimistic about the future volume of “Haimei Yuebai”

Guosheng SecuritiesNov 4 16:32

[Brokerage Focus] Northeast Securities maintains a 'buy' rating for Haohai Biotech (06826), citing the potential annual increase in its market share.

Golden Guardian Financial NewsNov 4 15:05

Haohai Biotechnology (06826.HK): Domestic high-end hyaluronic acid leader, R&D innovation creates growth engine

Northeast SecuritiesNov 1 00:00

Haohai Biotechnology (06826.HK): Hyaluronic acid maintains growth trend and looks forward to Haimei Yuebai's excellent performance

Northeast SecuritiesOct 28 00:00

Haohai Biotech (688366): Short-term pressure in Q3 to focus on medical and aesthetic pipeline progress

caitong securitiesOct 27 00:00

Haohai Biotech (688366): Short-term procurement price conversion is gaining momentum; innovative varieties are worth looking forward to

sinolinkOct 26 00:00

Haohai Biotech (688366): Performance is in line with expectations, high growth in the medical and aesthetic hyaluronic acid business

cscSep 22 00:00

Haohai Biotech (688366): Hyaluronic acid growth exceeds expectations, and the ophthalmology layout continues to be rich

Aug 23 08:36

Haohai Biotech (688366): Medicine and aesthetics continue to increase, and the localization process of ophthalmology accelerates

Aug 20 11:11

Haohai Biotech (688366): The 24H1 hyaluronic acid business continues to grow rapidly, and the research pipeline is rich in reserves

Aug 19 15:41

Haohai Biotech (688366): 24H1 performance is in line with expectations, focus on the new product Haimeiyue Baidu Sales

Aug 18 00:00

Haohai Biotech (688366) 2024 semi-annual report review: Hyaluronic acid maintains a high year-on-year growth trend, deducts non-profits and achieves steady growth

Aug 18 00:00

Haohai Biotech (688366): Innovative hyaluronic acid increased 51% year-on-year, and ophthalmology sales are gaining momentum

Aug 16 00:00

Haohai Biotech (688366) Company In-depth Research: Medicine and Aesthetics Drive Development Mergers and Acquisitions+Self-Research to Strengthen Competitive Advantages

Jun 19 00:00

Haohai Biotech (688366): The first quarter's performance grew rapidly, and the R&D pipeline continued to advance steadily

May 9 07:36

Haohai Biotech (688366): The performance is in line with expectations, and the medical, aesthetic and ophthalmology businesses are working together

May 7 07:21

Haohai Biotechnology (06826.HK): The Q1 profit side slightly exceeded expectations and the profitability was significantly optimized

Apr 30 00:00

Haohai Biotech (688366): Net profit after deducting non-return to mother increased 33%, expecting fourth-generation hyaluronic acid to be approved

Apr 30 00:00

Haohai Biotech (688366) First Coverage Report: Biomaterials Industry Leaders Build a Comprehensive Platform for Medical Devices+Medical and Aesthetic Consumption

Apr 17 16:41

Minsheng Securities released a research report on April 17 stating that it gave Haohai Biotech (688366.SH) a recommended rating. The main reasons for the rating include: 1) the company is a leader in the biomaterials segment, opening the development ceili

Zhitong FinanceApr 17 16:19